Brasada Capital Management LP Buys 250 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Share on StockTwits

Brasada Capital Management LP increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 20.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,500 shares of the medical research company’s stock after acquiring an additional 250 shares during the quarter. Brasada Capital Management LP’s holdings in Bio-Rad Laboratories were worth $499,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. BlackRock Inc. boosted its position in shares of Bio-Rad Laboratories by 1.2% during the second quarter. BlackRock Inc. now owns 1,950,805 shares of the medical research company’s stock worth $609,803,000 after acquiring an additional 22,263 shares during the last quarter. Atlanta Capital Management Co. L L C boosted its position in shares of Bio-Rad Laboratories by 0.7% during the second quarter. Atlanta Capital Management Co. L L C now owns 755,635 shares of the medical research company’s stock worth $236,204,000 after acquiring an additional 5,522 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Bio-Rad Laboratories by 3.9% during the second quarter. Russell Investments Group Ltd. now owns 411,262 shares of the medical research company’s stock worth $128,208,000 after acquiring an additional 15,486 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Bio-Rad Laboratories by 2.7% during the second quarter. UBS Asset Management Americas Inc. now owns 397,224 shares of the medical research company’s stock worth $124,168,000 after acquiring an additional 10,536 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Bio-Rad Laboratories by 107.5% during the second quarter. Point72 Asset Management L.P. now owns 285,019 shares of the medical research company’s stock worth $89,094,000 after acquiring an additional 147,643 shares during the last quarter. Hedge funds and other institutional investors own 62.30% of the company’s stock.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 1,089 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $333.08, for a total transaction of $362,724.12. Following the completion of the transaction, the executive vice president now owns 2,011 shares in the company, valued at $669,823.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy S. Ernst sold 310 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $320.00, for a total transaction of $99,200.00. Following the transaction, the executive vice president now owns 3,100 shares of the company’s stock, valued at approximately $992,000. The disclosure for this sale can be found here. Insiders have sold 7,876 shares of company stock valued at $2,634,905 in the last quarter. 27.84% of the stock is owned by company insiders.

BIO stock opened at $352.45 on Friday. Bio-Rad Laboratories, Inc. has a 52 week low of $220.05 and a 52 week high of $358.89. The company has a quick ratio of 3.36, a current ratio of 4.72 and a debt-to-equity ratio of 0.12. The company has a fifty day simple moving average of $340.30 and a two-hundred day simple moving average of $319.57. The firm has a market capitalization of $10.28 billion, a P/E ratio of 60.35, a price-to-earnings-growth ratio of 3.23 and a beta of 1.16.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, October 31st. The medical research company reported $1.61 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.36 by $0.25. Bio-Rad Laboratories had a net margin of 16.14% and a return on equity of 4.30%. The business had revenue of $560.60 million during the quarter, compared to analyst estimates of $561.40 million. During the same quarter last year, the business earned $0.91 earnings per share. Bio-Rad Laboratories’s quarterly revenue was up 2.8% compared to the same quarter last year. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 7.2 EPS for the current year.

BIO has been the subject of a number of research reports. Barclays upped their target price on shares of Bio-Rad Laboratories from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. They noted that the move was a valuation call. ValuEngine lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. Finally, Goldman Sachs Group upgraded shares of Bio-Rad Laboratories from a “buy” rating to a “conviction-buy” rating and set a $400.00 target price for the company in a research report on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Bio-Rad Laboratories currently has a consensus rating of “Buy” and a consensus price target of $378.75.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

See Also: New Google Finance Tool and Screening Stocks

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.